FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name an Forbes	H	2. Issuer Name and Ticker or Trading Symbol HERON THERAPEUTICS, INC. /DE/ HRTX									ck all applic	,		10% Ow	ner				
(Last) (First) (Middle) 4242 CAMPUS POINT COURT, SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 07/19/2024									Officer (give title Other (specify below)  EVP, Chief Development Officer				
(Street) SAN DIEGO CA 92121					4. If	Line)  Form filed											nt/Group Filing (Check Applicable d by One Reporting Person d by More than One Reporting		
(City) (State) (Zip)				Rı	Rule 10b5-1(c) Transaction Indication														
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.						ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code	Transaction Dis		Securities Acquired (A) isposed Of (D) (Instr. 3,			5. Amou Securitie Benefici Owned F	es Fo ially (D Following (I)		n: Direct c r Indirect E str. 4) (	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) (D)	or I	Price	Transaci (Instr. 3	on(s)			instr. 4)
Common Stock 07/19/					9/2024	4			М		3,87	5 A		(1) 99		,249		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date, Trans Code			of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		xpiration ate	Title	or Nu of	nount mber ares					
Restricted Stock Units	\$0.00	07/19/2024			M			3,875	(2)		(2)	Common Stock	3,	875	\$0.00	54,240	)	D	

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock
- 2. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

/s/ Kathryn Lester Attorney-in-07/22/2024 Fact for William P. Forbes

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.